International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies

Circulation

Volumn 136, Issue 20, 2017, Pages 1955-1975

  Angiolillo, Dominick J ^a   Rollini, Fabiana ^a   Storey, Robert F ^b   Bhatt, Deepak L ^c   James, Stefan ^d   Schneider, David J ^e   Sibbing, Dirk ^f,g   So, Derek Y F ^h   Trenk, Dietmar ⁱ   Alexopoulos, Dimitrios ^j   Gurbel, Paul A ^k   Hochholzer, Willibald ⁱ   De Luca, Leonardo ^l,n,o   Bonello, Laurent ^m   Aradi, Daniel ^p   Cuisset, Thomas ^q   Tantry, Udaya S ^k   Wang, Tracy Y ^r   Valgimigli, Marco ^s   Waksman, Ron ^t   Mehran, Roxana ^u   Montalescot, Gilles ^v   Franchi, Francesco ^a   Price, Matthew J ^w   more..

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF VERMONT   (United States)

^f UNIVERSITY OF MUNICH   (Germany)

^g DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^h UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

ⁱ UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^j UNIVERSITY OF ATHENS   (Greece)

^k INOVA HEART AND VASCULAR INSTITUTE   (United States)

^l San Giovanni Evangelista Hospital   (Italy)

^m HÔPITAL NORD   (France)

ⁿ Mediterranean Academic Association for Research and Studies in Cardiology   (France)

^o INSERM   (France)

^p SEMMELWEIS UNIVERSITY   (Hungary)

^q AIX MARSEILLE UNIVERSITY   (France)

^r DUKE UNIVERSITY MEDICAL CENTER   (United States)

^s BERN UNIVERSITY HOSPITAL   (Switzerland)

^t WASHINGTON HOSPITAL CENTER   (United States)

^u MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^v SORBONNE UNIVERSITÉ   (France)

^w SCRIPPS CLINIC   (United States)

more..

Author keywords

Drug interactions; Hemorrhage; P2Y12 receptor inhibitors; Pharmacodynamics; Platelet aggregation inhibitors; Thrombosis

Indexed keywords

CANGRELOR; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICAGRELOR; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ANTICOAGULANT THERAPY; ARTICLE; DRUG BINDING; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; HUMAN; INTERNATIONAL COOPERATION; MEDICAL EXPERT; PRACTICE GUIDELINE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CONSENSUS; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ASPIRIN; CONSENSUS; DRUG SUBSTITUTION; HUMANS; INTERNATIONALITY; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 85037674022     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.031164     Document Type: Article

References (100)

1. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-e651. doi: 10.1161/CIR.0b013e31823ba622.
2. Valgimigli M, Bueno H, Byrne RA, Collet J P, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) [published online ahead of print August 26, 2017]. Eur Heart J. doi: 10.1093/eurheartj/ehx419.https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehx419.
3. Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72:2087-2116. doi: 10.2165/11640880-000000000-00000.
4. Wallentin L, Becker RC, Budaj A, Cannon C P, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey R F, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327.
5. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. doi: 10.1056/NEJMoa0706482.
6. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12:30-47. doi: 10.1038/nrcardio.2014.156.
7. Sherwood MW, Wiviott SD, Peng SA, Roe MT, Delemos J, Peterson ED, Wang TY. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc. 2014;3:e000849.
8. Bueno H, Sinnaeve P, Annemans L, Danchin N, Licour M, Medina J, Pocock S, Sánchez-Covisa J, Storey RF, Jukema JW, Zeymer U, Van de Werf F; EPICOR Investigators. Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: insights from EPICOR, an international study of current practice patterns. Eur Heart J Acute Cardiovasc Care. 2016;5:3-12. doi: 10.1177/2048872614565912.
9. Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016;13:11-27. doi: 10.1038/nrcardio.2015.113.
10. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261-2273. doi: 10.1016/j.jacc.2013.07.101.
11. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36:1762-1771. doi: 10.1093/eurheartj/ehv104.
12. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50:126-142. doi: 10.1177/0091270009343005.
13. Bernlochner I, Morath T, Brown PB, Zhou C, Baker BA, Gupta N, Jakubowski JA, Winters KJ, Schömig A, Kastrati A, Sibbing D. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. Platelets. 2013;24:15-25. doi: 10.3109/09537104.2011.654003.
14. Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, Winters KJ, Li W, Angiolillo DJ. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. J Am Coll Cardiol. 2012;59:2338-2343. doi: 10.1016/j.jacc.2012.02.042.
15. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27:259-274. doi: 10.1111/j.1755-5922.2009.00096.x.
16. Gurbel PA, Bliden K P, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey R F. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577-2585. doi: 10.1161/CIRCULATIONAHA.109.912550.
17. Franchi F, Rollini F, Muñiz-Lozano A, Cho JR, Angiolillo DJ. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013;11:1279-1291. doi: 10.1586/14779072.2013.837701.
18. Rollini F, Franchi F, Cho JR, DeGroat C, Bhatti M, Muniz-Lozano A, Singh K, Ferrante E, Wilson RE, Dunn EC, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J. 2016;37:2722-2730. doi: 10.1093/eurheartj/ehv744.
19. Pourdjabbar A, Hibbert B, Chong AY, Le May MR, Labinaz M, Simard T, Ramirez FD, Lugomirski P, Maze R, Froeschl M, Glover C, Dick A, Marquis J F, Bernick J, Wells G, So DY; CAPITAL Investigators. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome: the CAPITAL OPTI-CROSS Study. Thromb Haemost. 2017;117:303-310. doi: 10.1160/TH16-04-0340.
20. Angiolillo DJ, Curzen N, Gurbel P, Vaitkus P, Lipkin F, Li W, Jakubowski JA, Zettler M, Effron MB, Trenk D. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 Study (Switching Anti Platelet-2). J Am Coll Cardiol. 2014;63:1500-1509. doi: 10.1016/j.jacc.2013.11.032.
21. Franchi F, Faz GT, Rollini F, Park Y, Cho JR, Thano E, Hu J, Kureti M, Aggarwal N, Durairaj A, Been L, Zenni MM, Guzman LA, Suryadevara S, Antoun P, Bass TA, Angiolillo DJ. Pharmacodynamic effects of switching from prasug-rel to ticagrelor: results of the prospective, randomized SWAP-3 study. JACC Cardiovasc Interv. 2016;9:1089-1098. doi: 10.1016/j.jcin.2016.02.039.
22. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. doi: 10.1161/CIRCULATIONAHA.106.685313.
23. Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo J F, Shaburishvili T, Huber K, Prats J, Liu T, Harrington RA, Becker RC. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34:44-55. doi: 10.1007/s11239-012-0737-3.
24. Rollini F, Franchi F, Tello-Montoliu A, Patel R, Darlington A, Ferreiro JL, Cho JR, Muñiz-Lozano A, Desai B, Zenni MM, Guzman LA, Bass TA, Angiolillo DJ. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC Cardiovasc Interv. 2014;7:426-434. doi: 10.1016/j.jcin.2013.11.019.
25. Rollini F, Franchi F, Thano E, Faz G, Park Y, Kureti M, Cho JR, Been L, Bass TA, Angiolillo DJ. In vitro pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in ticagrelor-treated patients. JACC Cardiovasc Interv. 2017;10:1374-1375. doi: 10.1016/j.jcin.2017.04.027.
26. Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P. Pharmacody-namic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7:435-442. doi: 10.1016/j.jcin.2013.08.017.
27. Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26:42-48. doi: 10.1097/MCA.0000000000000158.
28. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307:265-274. doi: 10.1001/jama.2011.2002.
29. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008;121:527-534. doi: 10.1016/j.thromres.2007.05.020.
30. Schneider DJ, Agarwal Z, Seecheran N, Gogo P. Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation. J Interv Cardiol. 2015;28:415-419. doi: 10.1111/joic.12229.
31. Schneider DJ. Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists. Coron Artery Dis. 2016;27:65-69. doi: 10.1097/MCA.0000000000000311.
32. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay J F, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999-1010. doi: 10.1056/NEJMoa1308075.
33. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cintezǎ M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-1309. doi: 10.1056/NEJMoa1205512.
34. Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen J F, Bolognese L, Cantor WJ, Cequier A, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Stibbe O, Ecollan P, Heutz WM, Swahn E, Collet J P, Willems F F, Baradat C, Licour M, Tsatsaris A, Vicaut E, Hamm CW; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016-1027. doi: 10.1056/NEJMoa1407024.
35. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-1800. doi: 10.1056/NEJMoa1500857.
36. Alexopoulos D, Xanthopoulou I, Deftereos S, Sitafidis G, Kanakakis I, Hamilos M, Angelidis C, Petousis S, Stakos D, Parissis H, Vavouranakis M, Davlouros P, Goudevenos J, Stefanadis C. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J. 2014;167:68-76.e2. doi: 10.1016/j.ahj.2013.10.010.
37. Clemmensen P, Grieco N, Ince H, Danchin N, Goedicke J, Ramos Y, Schmitt J, Goldstein P; MULTIPRAC study investigators. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel: the European MULTIP-RAC Registry. Eur Heart J Acute Cardiovasc Care. 2015;4:220-229. doi: 10.1177/2048872614547449.
38. Bagai A, Peterson ED, Honeycutt E, Effron MB, Cohen DJ, Goodman SG, Anstrom KJ, Gupta A, Messenger JC, Wang TY. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the TRANSLATE-ACS study. Eur Heart J Acute Cardiovasc Care. 2015;4:499-508. doi: 10.1177/2048872614564082.
39. Schiele F, Puymirat E, Bonello L, Meneveau N, Collet J P, Motreff P, Ravan R, Leclercq F, Ennezat P V, Ferrières J, Simon T, Danchin N. Switching between thienopyridines in patients with acute myocardial infarction and quality of care. Open Heart. 2016;3:e000384. doi: 10.1136/openhrt-2015-000384.
40. De Luca L, Leonardi S, Cavallini C, Lucci D, Musumeci G, Caporale R, Abrignani MG, Lupi A, Rakar S, Gulizia MM, Bovenzi FM, De Servi S; EYESHOT Investigators. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: the EYESHOT study. Eur Heart J Acute Cardiovasc Care. 2015;4:441-452. doi: 10.1177/2048872614560505.
41. Bagai A, Wang Y, Wang TY, Curtis J P, Gurm HS, Shah B, Cheema AN, Peterson ED, Saucedo JF, Granger CB, Roe MT, Bhatt DL, McNamara RL, Alexander K P. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the National Cardiovascular Data Registry. Circ Cardiovasc Interv. 2014;7:585-593. doi: 10.1161/CIRCINTERVENTIONS.114.001555.
42. De Luca G, Verdoia M, Schaffer A, Suryapranata H, Parodi G, Antoniucci D, Marino P. Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience. J Thromb Thrombolysis. 2014;38:388-394. doi: 10.1007/s11239-013-1039-0.
43. Loh JP, Pendyala LK, Kitabata H, Torguson R, Chen F, Kent KM, Satler LF, Suddath WO, Pichard AD, Waksman R. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2013;111:841-845. doi: 10.1016/j.amjcard.2012.11.058.
44. Almendro-Delia M, Blanco Ponce E, Gomez-Domínguez R, Gonzalez-Matos C, Lobo-Gonzalez M, Caballero-Garcia A, Hidalgo-Urbano R, Cruz-Fernandez MJ, Garcia-Rubira JC. Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome: an analysis from the "real world." J Thromb Thrombolysis. 2015;39:499-507. doi: 10.1007/s11239-014-1139-5.
45. Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, Baker BA, Messenger JC, Cohen DJ, Wang TY; TRANSLATE-ACS Investigators. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J. 2017;183:62-68. doi: 10.1016/j.ahj.2016.10.006.
46. Bagai A, Peterson ED, McCoy LA, Effron MB, Zettler ME, Stone GW, Henry TD, Cohen DJ, Schulte PJ, Anstrom KJ, Wang TY. Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. Am Heart J. 2017;187:19-28. doi: 10.1016/j.ahj.2017.02.003.
47. De Luca L, D'Ascenzo F, Musumeci G, Saia F, Parodi G, Varbella F, Marchese A, De Servi S, Berti S, Bolognese L. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention. 2017;13:459-466. doi: 10.4244/EIJ-D-17-00092.
48. Angiolillo DJ, Saucedo J F, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56:1017-1023. doi: 10.1016/j.jacc.2010.02.072.
49. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey R F, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel D V, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188-1199. doi: 10.1161/CIRCULATIONAHA.109.919456.
50. Payne CD, Li YG, Brandt JT, Jakubowski JA, Small DS, Farid NA, Salazar DE, Winters KJ. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets. 2008;19:275-281. doi: 10.1080/09537100801891640.
51. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E; PRINCIPLETIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932. doi: 10.1161/CIRCULATIONAHA.107.740324.
52. Montalescot G, Sideris G, Cohen R, Meuleman C, Bal dit Sollier C, Barthélémy O, Henry P, Lim P, Beygui F, Collet J P, Marshall D, Luo J, Petitjean H, Drouet L. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome: the randomised, double-blind ACAPULCO study. Thromb Haemost. 2010;103:213-223. doi: 10.1160/TH09-07-0482.
53. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59:2159-2164. doi: 10.1016/j.jacc.2012.02.026.
54. Diodati JG, Saucedo J F, French JK, Fung AY, Cardillo TE, Henneges C, Effron MB, Fisher HN, Angiolillo DJ. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. Circ Cardiovasc Interv. 2013;6:567-574. doi: 10.1161/CIRCINTERVENTIONS.112.000063.
55. Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE trial. Circ Cardiovasc Interv. 2012;5:698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463.
56. Lhermusier T, Voisin S, Murat G, Mejean S, Garcia C, Bataille V, Lipinski MJ, Carrié D, Sié P. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity. Int J Cardiol. 2014;174:874-876. doi: 10.1016/j.ijcard.2014.04.208.
57. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol. 2012;60:193-199. doi: 10.1016/j.jacc.2012.03.050.
58. Koul S, Andell P, Martinsson A, Smith JG, Scherstén F, Harnek J, Götberg M, Norström E, Björnsson S, Erlinge D. A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. BMC Cardiovasc Disord. 2014;14:189. doi: 10.1186/1471-2261-14-189.
59. Cuisset T, Gaborit B, Dubois N, Quilici J, Loosveld M, Beguin S, Loundou AD, Moro PJ, Morange PE, Alessi MC, Dutour A, Bonnet JL. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Int J Cardiol. 2013;168:523-528. doi: 10.1016/j.ijcard.2012.09.214.
60. Nührenberg TG, Trenk D, Leggewie S, Ristau I, Amann M, Stratz C, Hochholzer W, Valina CM, Neumann FJ. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study. Platelets. 2013;24:549-553. doi: 10.3109/09537104.2012.736045.
61. Parodi G, De Luca G, Bellandi B, Comito V, Valenti R, Marcucci R, Carrabba N, Migliorini A, Ramazzotti RN, Gensini G F, Abbate R, Antoniucci D. Switching from clopidogrel to prasugrel in patients having coronary stent implantation. J Thromb Thrombolysis. 2014;38:395-401. doi: 10.1007/s11239-013-1040-7.
62. Aradi D, Tornyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol. 2014;63:1061-1070. doi: 10.1016/j.jacc.2013.12.023.
63. Mayer K, Schulz S, Bernlochner I, Morath T, Braun S, Hausleiter J, Massberg S, Schunkert H, Laugwitz KL, Kastrati A, Sibbing D. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity: results of the ISAR-HPR registry. Thromb Haemost. 2014;112:342-351. doi: 10.1160/TH13-10-0874.
64. Lhermusier T, Lipinski MJ, Drenning D, Marso S, Chen F, Torguson R, Waksman R. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. J Interv Cardiol. 2014;27:365-372. doi: 10.1111/joic.12139.
65. Caiazzo G, De Rosa S, Torella D, Spaccarotella C, Mongiardo A, Giampà S, Micieli M, Palella E, Gulletta E, Indolfi C. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. Circ Cardiovasc Interv. 2014;7:104-112. doi: 10.1161/CIRCINTERVENTIONS.113.000512.
66. Hibbert B, Maze R, Pourdjabbar A, Simard T, Ramirez FD, Moudgil R, Blondeau M, Labinaz M, Dick A, Glover C, Froeschl M, Marquis JF, So DY, Le May MR. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PLoS One. 2014;9:e92078. doi: 10.1371/journal.pone.0092078.
67. Michelson AD, Frelinger AL 3rd, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos N P, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD; TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009;30:1753-1763. doi: 10.1093/eurheartj/ehp159.
68. Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the Switching Anti-Platelet (SWAP) study. Thromb Haemost. 2013;109:347-355. doi: 10.1160/TH12-06-0378.
69. Bliden KP, Tantry US, Storey RF, Jeong YH, Gesheff M, Wei C, Gurbel PA. The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. Am Heart J. 2011;162:160-165. doi: 10.1016/j.ahj.2010.11.025.
70. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon C P, Becker RC, Wallentin L. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56:1456-1462. doi: 10.1016/j.jacc.2010.03.100.
71. Alexopoulos D, Xanthopoulou I, Perperis A, Goudevenos J, Hamilos M, Sitafidis G, Kanakakis I, Vavouranakis M, Giannopoulos G, Barampoutis N, Deftereos S, Lekakis J. Dyspnea in patients treated with P2Y12 receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry. Platelets. 2017;2:1-7.
72. Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P, Hamm C, Špinar J, Kiss RG, Dalby AJ, Medina FA, Kontny F, Aylward PE, Jensen EC, Held P, Braunwald E, Sabatine MS. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol. 2016;1:425-432. doi: 10.1001/jamacardio.2016.1017.
73. Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G, Fourcade L, Mouret JP, Lambert M, Verdier V, Morange PE, Alessi MC, Bonnet JL. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (Timing of Platelet Inhibition After Acute Coronary Syndrome) randomized study [published online ahead of print May 16, 2017]. Eur Heart J. doi: 10.1093/eurheartj/ehx175.https://academic.oup.com/eurheartj/article-abstract/doi/10.1093/eurheartj/ehx175/3827697/Beneft-of-switching-dual-antiplatelet-therapy?redirectedFrom=fulltext..
74. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Komócsi A, Dézsi CA, Holdt L, Felix SB, Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann FJ, Koltowski L, Mehilli J, Huczek Z, Massberg S; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390:1747-1757. doi: 10.1016/S0140-6736(17)32155-4.
75. Price MJ, Berger PB, Teirstein PS, Tanguay J F, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand O F, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon C P, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097-1105. doi: 10.1001/jama.2011.290.
76. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, Vicaut E, Montalescot G; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100-2109. doi: 10.1056/NEJ-Moa1209979.
77. Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, Carrié D, Belle L, Souteyrand G, Aubry P, Sabouret P, du Fretay XH, Beygui F, Bonnet JL, Lattuca B, Pouillot C, Varenne O, Boueri Z, Van Belle E, Henry P, Motreff P, Elhadad S, Salem JE, Abtan J, Rousseau H, Collet J P, Vicaut E, Montalescot G; ANTARCTIC Investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388:2015-2022. doi 10.1016/S0140-6736(16)31323-X
78. Moon JY, Franchi F, Rollini F, Rivas Rios JR, Kureti M, Cavallari LH, Angiolillo DJ. Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Rev Clin Pharmacol. 2017;Oct 12:1-14. doi 10.1080/17512433.2017.1353909.
79. Kerneis M, Silvain J, Abtan J, Cayla G, O'Connor SA, Barthélémy O, Vignalou JB, Beygui F, Brugier D, Martin R, Collet JP, Montalescot G. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv. 2013;6:158-165. doi:10 1016/j.jcin.2012.09.012
80. Deharo P, Pons C, Pankert M, Bonnet G, Quilici J, Grosdidier C, Beguin S, Morange P, Alessi MC, Bonnet JL, Cuisset T. Effectiveness of switching "hyper responders" from prasugrel to clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. Int J Cardiol. 2013;168:5004-5005. doi:10.1016/jijcard.2013.07.121
81. Vaduganathan M, Qamar A, Singh A, Venkateswaran RV, Szumita PM, Croce KJ, Mauri L, Leopold JA, Shah PB, Sobieszczyk P, Faxon DP, Bhatt DL. Cangrelor use since FDA approval: a single-center, real-world experience at a tertiary care hospital. J Am Coll Cardiol. 2017;69:463-464. doi 10.1016/j.jacc.2016.11.017
82. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008;6:1153-1159. doi:10.1111/j.1538-7836.2008.03020.x
83. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303-1313. doi:10.1056/NEJ-Moa1300815
84. Badreldin HA, Carter D, Cook BM, Qamar A, Vaduganathan M, Bhatt DL. Safety and tolerability of transitioning from cangrelor to ticagrelor in patients who underwent percutaneous coronary intervention. Am J Cardiol 2017;120:359-361. doi:10.1016/j.amjcard.2017.04.034
85. Franchi F, Rollini F, Park Y, Angiolillo DJ. A safety evaluation of cangrelor in patients undergoing PCI. Expert Opin Drug Saf. 2016;15:275-285. doi 10.1517/14740338.2016.1133585
86. Judge HM, Buckland RJ, Jakubowski JA, Storey RF. Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. Platelets. 2016;27:191-195. doi 10.3109/09537104.2015.1069809
87. Hochholzer W, Kleiner P, Younas I, Valina CM, Löffelhardt N, Amann M, Bömicke T, Ferenc M, Hauschke D, Trenk D, Neumann FJ, Stratz C. Randomized Comparison of oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor: the ExcelsiorLOAD2 Trial. JACC Cardiovasc Interv. 2017;10:121-129. doi:10.1016/j.jcin.2016.10.004
88. Thomas MR, Morton AC, Hossain R, Chen B, Luo L, Shahari NN, Hua P, Beniston RG, Judge HM, Storey RF. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost. 2016;116:96-102. doi:10.1160/TH16-02-0102
89. Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, Tsatsaris A, Baradat C, Salhi N, Hamm CW, Lapostolle F, Lassen JF, Collet JP, Ten Berg JM, Van't Hof AW, Montalescot G. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction: the PRIVATE-ATLANTIC study. Thromb Haemost. 2016;116:369-378. doi:10.1160/TH15-12-0944
90. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszałł MP, Rose D, Koziński M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016;37:245-252. doi:10.1093/eurheartj/ehv547
91. Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, Stavrou K, Migliorini A, Antoniucci D, Tamburino C, Alexopoulos D. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8: e001593. doi:10.1161/CIRCINTERVENTIONS.114.001593
92. Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol. 2017;14:361-379. doi: 10.1038/nrcardio.2017.18.
93. Cangrelor United States full prescribing information. https://resources.chiesiusa.com/Kengreal/KENGREAL-US-PI.pdf. Accessed October 15, 2017.
94. Cangrelor European Medicines Agency full prescribing information. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/003773/WC500188098.pdf. Accessed June 3, 2017.
95. Capodanno D, Angiolillo DJ. Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and non-cardiac surgery. Circulation. 2013;128:2785-2798. doi: 10.1161/CIRCULATIONAHA.113.003675.
96. Rossini R, Tarantini G, Musumeci G, Masiero G, Barbato E, Calabrò P, Capodanno D, Leonardi S, Lettino M, Limbruno U, Menozzi A, Marchese A, Saia F, Valgimigli M, Ageno M, Falanga A, Corcione A, Locatelli A, Montorsi M, Piazza D, Stella A, Bozzani A, Parolari A, Carone R, Angiolillo DJ. Italian Society of Invasive Cardiology (SICI-GISE), Italian Society for Haemostasis and Thrombosis (SISET), Italian Society of Anesthesia and Intensive Care Medicine (SIAARTI), Italian Society of Surgery (SIC), Italian Society for Cardiac Surgery (SICCH), Italian Society of Vascular and Endovascular Surgery (SICVE), Italian Society of Urology (SIU), Italian Orthopaedic Society (SIOT), Italian Society of Thoracic Surgeons (SICT), Italian Federation of scientific Societies of Digestive System Diseases (FISMAD), Italian Society of Digestive Endoscopy (SIED), Italian Association of hospital Gastroenterology and Digestive Endoscopy (AIGO), Italian Association of Gastroenterology and Digestive Endoscopy (SIGE), Italian Society of Maxillofacial Surgery (SICMF), Italian Society of Reconstructive Plastic Surgery and Aesthetics (SICPRE), Italian Society of Ginecology and Obstetrics (SIGO), Italian Society of Neurosurgery (SINch), Italian Association of Hospital Pulmonologist (AIPO), Italian Society of Periodontology (SIdP), Italian Society of Ophthalmology (SOI), Italian Association of Hospital Otorhinolaryngologist (AOOI), Italian Association of Hospital Surgeons (ACOI), Association of Obstetricians Gynecologists Italian Hospital (AOGOI). A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery: surgery after stenting 2. JACC Cardiovasc Interv. 2017; In press.
97. Halim SA, Rao SV. Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes. Curr Drug Targets. 2011;12:1831-1835. doi: 10.2174/138945011797635876.
98. Muñiz-Lozano A, Rollini F, Franchi F, Angiolillo DJ. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. Ther Adv Cardiovasc Dis. 2013;7:197-213. doi: 10.1177/1753944713487781.
99. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon D P. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective-2016 update. Circ Cardiovasc Interv. 2016;9:e004395. doi: 10.1161/CIRCINTERVENTIONS.116.004395.
100. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Storey R F, Bueno H, Collet J P, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155-3179. doi: 10.1093/eurheartj/ehu298.